Viibryd Is the Latest Rx Med for Depression

May 2018

Viibryd (VYE-brid, vilazodone) will be the latest antidepressant to hit pharmacy shelves.

Think of Viibryd as similar to Trintellix (vortioxetine). Both work similarly to increase serotonin levels in patients with depression.

Expect doses on Viibryd Rxs to "start low and go up slow" to help minimize stomach-related side effects. For instance, a patient may get 10 mg by mouth once daily for 7 days...followed by 20 mg daily for 7 days...then increased to the max dose of 40 mg daily, if needed.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Communication Help Patients Feel at Ease When Discussing Sensitive Topics
Depression Viibryd Is the Latest Rx Med for Depression
Practice Find Alternatives to Meds Discontinued by the Manufacturer
ADHD Foquest and Act-Methylphenidate ER Will Compete With Other ADHD Meds
Vaccines Develop Strategies to Flag Patients Eligible for Hep B Vaccine
Ophthalmology Prevent Common Eye Drop Errors
Pregnancy Help With Safe Use of GI Meds in Pregnant Patients
HIV & AIDS Encourage Adherence With Meds Used to Prevent HIV
Appropriate Med Use Help Patients Get Off Unneeded Meds
Infectious Diseases Watch for Rxs for Acute Infections in Patients on Chronic Antibiotics

Viibryd Is the Latest Rx Med for Depression

Practical advice for a better career, with unlimited access to CE

Table of Contents